EntreMed, Inc.

EntreMed's patent covers broad range of indications for 2-methoxyestradiol

Published in Drug Law Weekly, April 11th, 2006

EntreMed, Inc. (ENMD) announced the issuance of U.S. patent No. 7,012,070 covering methods of treatment for a broad range of indications with its lead clinical-stage compound, 2-methoxyestradiol (2ME2).

Panzem NCD, an oral formulation of 2ME2, is currently in phase II clinical trials for cancer. Panzem is also in preclinical development for rheumatoid arthritis.

Patent No. 7,012,070, entitled "Estrogenic Compounds as Anti-Mitotic Agents," contains claims granted by the U.S. Patent Office covering 2ME2 for the treatment of multiple indications, including cancer and inflammatory disorders such as rheumatoid arthritis.

The patent...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2006-04-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry